Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy

Chromosomal chaos and tumor immunity Cancer immunotherapy produces durable clinical responses in only a subset of patients. Identification of tumor characteristics that correlate with responses could lead to predictive biomarkers and shed light on causal mechanisms. Davoli et al. found that human tumors with extensive aneuploidy—i.e., that display a highly abnormal number of chromosomes and chromosomal segments—express fewer markers of the immune cells responsible for tumor destruction. In a retrospective analysis of clinical trial data, they found that melanoma patients with highly aneuploid tumors were less likely to benefit from immune checkpoint blockade therapy than patients whose tumors had a more normal…

• UD
  U.S. Department of Defense
• HH
  Howard Hughes Medical Institute
• VA
  Virginia and D.K. Ludwig Fund for Cancer Research
• NI
  National Institutes of Health